Advertisement
IDXX vs SYK
Which Stock Would AI Choose? IDEXX Laboratories (IDXX) vs. Stryker Corporation (SYK) Stock Comparison
Key Takeaways
- IDXX (IDEXX Laboratories) is a high-margin veterinary diagnostics leader, while SYK (Stryker Corporation) is a diversified medical-technology giant spanning orthopaedics, MedSurg, and neurotechnology.
- Both companies reported strong recent quarterly beats, but their stock-price behavior diverged sharply on valuation and sector-specific risks.
- IDXX delivered accelerating diagnostics revenue growth and raised guidance, yet softer U.S. veterinary-visit trends continue to pressure sentiment.
- SYK recovered from a first-quarter cybersecurity disruption and rebounded to roughly 9% organic sales growth, though execution risks linger.
- IDXX trades at a premium valuation multiple, while SYK trades below its own five-year median, creating contrasting risk-reward profiles.
- Relative performance and market positioning favor different investor styles: growth-oriented quality for IDXX versus turnaround-and-recovery for SYK.
Introduction
Investors evaluating healthcare exposure often weigh specialized, high-growth franchises against diversified industry leaders. This stock comparison examines IDXX (IDEXX Laboratories), the dominant player in companion-animal diagnostics, and SYK (Stryker Corporation), a global medical-technology company serving hospitals and surgical markets. Both operate with durable recurring-revenue models, yet their recent market positioning differs meaningfully. Growth investors may be drawn to IDXX's recurring diagnostics economics and premium margins, while value-conscious and turnaround-focused investors may find SYK's below-history valuation and recovery narrative more compelling. Understanding the contrasts in business model, momentum, and risk helps clarify which profile aligns with a given portfolio objective.
IDXX Overview and Recent Performance
IDXX, or IDEXX Laboratories, develops diagnostic instruments, consumables, and veterinary software primarily for companion-animal practices, alongside water and livestock testing. Its flagship Companion Animal Group (CAG) diagnostics business generates highly recurring revenue from instrument placements, reference laboratory testing, and rapid assays. In recent quarters, the company posted accelerating results, with second-quarter revenue rising roughly 10% year over year and recurring CAG diagnostics revenue growing about 10% organically, supported by higher testing utilization, net customer gains, and an expanding premium-instrument installed base. Gross margins expanded to around 64%, and operating margin reached approximately 35%.
Management raised its full-year earnings outlook, reflecting confidence in continued diagnostics adoption and product innovation such as the inVue Dx and Cancer Dx platforms. Despite this operational strength, sentiment has been tempered by persistent softness in U.S. veterinary visit volumes—clinical visits have declined modestly while wellness visits fell more steeply—as well as foreign-exchange headwinds. The shares have underperformed in recent market activity, with a notable year-to-date decline and a forward price-to-earnings (P/E) ratio that remains elevated relative to the broader medical-equipment industry, keeping the risk-reward debate balanced.
SYK Overview and Recent Performance
SYK, or Stryker Corporation, is a diversified medical-technology leader spanning orthopaedic implants, MedSurg equipment, neurotechnology, and emergency-care products. Its growth is anchored by recurring consumables and a growing robotics franchise built around the Mako platform. Recent market activity was shaped by a March cybersecurity incident that disrupted global production, shipping, and ordering, compressing first-quarter sales growth to roughly 2.6%. The company rebounded sharply in the second quarter, with revenue up about 9.4% year over year and organic growth near 9%, as plants returned to normal operation and capital orders were fulfilled. Adjusted earnings rose approximately 18%.
Stryker narrowed—rather than raised—its full-year guidance, reflecting continued uncertainty around vascular supply constraints, cybersecurity remediation costs, and a planned CEO transition effective at the start of 2027. Despite the recovery, the stock trades below its five-year median valuation multiple, suggesting the market is weighing execution risk against a robust product pipeline that includes record Mako installations, the Mako Shoulder launch, and the Pangea trauma platform. Analyst sentiment remains broadly favorable, but recent performance has been uneven relative to its own history.
Trending AI Robots
For traders seeking a data-driven edge, Tickeron's Trending AI Robots page curates a focused selection of AI trading bots from a much larger ecosystem. Tickeron hosts hundreds of AI Trading Bots that monitor thousands of tickers, each operating with distinct trading styles, strategies, timeframes, and performance statistics. Because market conditions change constantly, only the bots best suited to the current environment earn a place in this curated section. The platform highlights bots with varied approaches—ranging from swing trading to intraday models—allowing traders to review measurable statistics before exploring a particular strategy. Whether you follow IDXX, SYK, or the broader market, browsing the Trending AI Robots page offers a practical starting point for evaluating algorithm-driven ideas.
Head-to-Head Comparison
The two companies occupy different lanes of the healthcare sector. IDXX is a focused niche leader with an installed-base "razor-and-blade" model, earning roughly two-thirds gross margins from recurring consumables and testing. SYK is a far larger, diversified operator with a revenue base roughly five times IDXX's, spanning capital equipment and consumables across hospital and surgical settings. Growth drivers differ accordingly: IDXX depends on diagnostic frequency and pet-owner spending trends, while SYK hinges on procedural volumes, hospital capital expenditure (CapEx), and robotics adoption.
On recent momentum, IDXX has delivered consistent operational beats but faces a softer demand backdrop and a valuation that leaves less room for error. SYK showed a more volatile path—disruption followed by recovery—yet trades at a comparatively modest multiple. Risk factors also diverge: IDXX's primary exposure is consumer-driven veterinary traffic, while SYK's risks include supply-chain disruptions, integration of acquisitions, and leadership transition. From a market-sentiment standpoint, IDXX is a high-quality compounder trading below its own historical peaks but above industry averages, whereas SYK is a recovery story priced more defensively.
Tickeron AI Verdict
Weighing trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would likely tilt toward IDXX in the current environment—with measured confidence. IDXX's recurring-revenue model, expanding margins, and upwardly revised earnings guidance offer a steadier fundamental signal than SYK's still-normalizing recovery from operational disruption. However, the verdict is probabilistic rather than definitive. SYK's below-median valuation and deep product pipeline present a credible counter-case, particularly if the company converts its recovery into sustained margin expansion. The AI would likely frame IDXX as the more consistent quality trend and SYK as the higher-uncertainty, potentially higher-upside alternative—an outcome that depends on each investor's tolerance for volatility and valuation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDXX is a StrongBuy and SYK is a StrongBuy.
Momentum Indicator for IDXX turns positive, indicating new upward trend
IDXX saw its Momentum Indicator move above the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned positive. In 56 of the 93 cases, the stock moved higher in the following days. The odds of a move higher are at 60%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for IDXX just turned positive on September 22, 2026. Looking at past instances where IDXX's MACD turned positive, the stock continued to rise in 19 of 41 cases over the following month. The odds of a continued upward trend are 46%.
IDXX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IDXX crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 22 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 59%.
Following a +5.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDXX advanced for three days, in 174 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDXX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
IDXX broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IDXX entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating fairly steady price growth. IDXX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (27.689) is normal, around the industry mean (66.046). P/E Ratio (39.606) is within average values for comparable stocks, (2.422). Projected Growth (PEG Ratio) (2.894) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (9.042) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDXX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
SYK in upward trend: price rose above 50-day moving average on October 20, 2026
SYK moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 24 of 42 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 57%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on SYK as a result. In 48 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 53%.
The Moving Average Convergence Divergence (MACD) for SYK just turned positive on September 28, 2026. Looking at past instances where SYK's MACD turned positive, the stock continued to rise in 23 of 44 cases over the following month. The odds of a continued upward trend are 52%.
Following a +3.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYK advanced for three days, in 171 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.
SYK broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SYK entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. SYK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.910) is normal, around the industry mean (2.874). P/E Ratio (31.560) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (1.289) is also within normal values, averaging (11.052). Dividend Yield (0.011) settles around the average of (0.009) among similar stocks. P/S Ratio (4.259) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 76 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
IDXX | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 32 | 37 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 81 Overvalued | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 76 | |
SMR RATING 1..100 | 16 | 52 | |
PRICE GROWTH RATING 1..100 | 49 | 56 | |
P/E GROWTH RATING 1..100 | 71 | 83 | |
SEASONALITY SCORE 1..100 | 2 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SYK's Valuation (76) in the Medical Specialties industry is in the same range as IDXX (81). This means that SYK’s stock grew similarly to IDXX’s over the last 12 months.
SYK's Profit vs Risk Rating (76) in the Medical Specialties industry is in the same range as IDXX (100). This means that SYK’s stock grew similarly to IDXX’s over the last 12 months.
IDXX's SMR Rating (16) in the Medical Specialties industry is somewhat better than the same rating for SYK (52). This means that IDXX’s stock grew somewhat faster than SYK’s over the last 12 months.
IDXX's Price Growth Rating (49) in the Medical Specialties industry is in the same range as SYK (56). This means that IDXX’s stock grew similarly to SYK’s over the last 12 months.
IDXX's P/E Growth Rating (71) in the Medical Specialties industry is in the same range as SYK (83). This means that IDXX’s stock grew similarly to SYK’s over the last 12 months.
| IDXX | SYK | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 73% | 2 days ago 58% |
| Stochastic ODDS (%) | 2 days ago 74% | 2 days ago 50% |
| Momentum ODDS (%) | 2 days ago 60% | 2 days ago 53% |
| MACD ODDS (%) | 2 days ago 46% | 2 days ago 52% |
| TrendWeek ODDS (%) | 2 days ago 61% | 2 days ago 56% |
| TrendMonth ODDS (%) | 2 days ago 53% | 2 days ago 50% |
| Advances ODDS (%) | 8 days ago 60% | 4 days ago 56% |
| Declines ODDS (%) | 17 days ago 69% | 10 days ago 52% |
| BollingerBands ODDS (%) | 2 days ago 77% | 2 days ago 70% |
| Aroon ODDS (%) | 2 days ago 68% | 2 days ago 45% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IDXX’s FA Score shows that 1 FA rating(s) are green while SYK’s FA Score has 0 green FA rating(s).
- IDXX’s FA Score: 1 green, 4 red.
- SYK’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IDXX’s TA Score shows that 5 TA indicator(s) are bullish while SYK’s TA Score has 4 bullish TA indicator(s).
- IDXX’s TA Score: 5 bullish, 5 bearish.
- SYK’s TA Score: 4 bullish, 5 bearish.
Price Growth
IDXX (@Medical Specialties) experienced а +3.58% price change this week, while SYK (@Medical/Nursing Services) price change was +4.72% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +1.54%. For the same industry, the average monthly price growth was -5.91%, and the average quarterly price growth was +42.02%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.53%. For the same industry, the average monthly price growth was -9.75%, and the average quarterly price growth was -10.71%.
Reported Earning Dates
IDXX is expected to report earnings on Nov 02, 2026.
SYK is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Medical Specialties (+1.54% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (-0.53% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement